the concerning part is the animal tox study, how long that takes, and if it precludes an NDA submission to the FDA.
PER did a 9x month monkey tox study, and had some issues in getting monkey availability. If LTP need to do something similar, no way this is getting approved by the FDA next year.
Not sure what animal is needed for LTP and how long this study will have to go for. But without more details on this, only thing I am concerned about - maybe i have missed more details on this anyway. And, just impacts timing for approval rather than the risky part of actually demonstrating safety then efficacy etc.
But overall I am happy and would much prefer to be cashed up through a year in which they are prepping for NDA submission and marketing in Australia. BOT raised $75M for prepping marketing and so forth for FDA approval. They are a bit ahead but not too far.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)